- Home
- VRXA vs TLSA Comparison
VRXA vs TLSA Comparison
Compare VRXA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRXA | TLSA |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | Germany | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.4M | 145.1M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VRXA | TLSA |
|---|---|---|
| Price | $1.15 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.08 |
| AVG Volume (30 Days) | 278.2K | ★ 483.5K |
| Earning Date | N/A | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.76 |
| 52 Week High | $4.50 | $1.95 |
Technical Indicators
Market Signals| Indicator | VRXA | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 33.61 |
| Support Level | $1.04 | $0.76 |
| Resistance Level | $1.41 | $1.17 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 45.00 | 6.61 |
Price Performance
Historical ComparisonAbout VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.